Individuals
Businesses
Company
Intelligence
News
African Capital Markets
EnglishEnglish
share on twittershare on linkedinshare on facebookshare to whatsapp
share on mail
share on instagram

Nigeria-based biotech startup 54gene to shut down

Daba finance invest in Africa
STARTUP VENTURE CAPITALSeptember 28, 2023 at 8:39 PM UTC

Genomics startup 54gene has initiated the process of winding down its operations, according to sources connected to the company, as confirmed by TechCabal. The process began in July 2023, and by September, the company's website was no longer accessible. Additionally, the PR agency that had represented 54gene for a significant portion of its existence informed TechCabal that they were no longer working with the company. This revelation follows earlier unconfirmed reports about the company's financial troubles.


Founded in 2019, 54gene was established by Dr. Abasi Ene-Obong, who successfully raised $45 million through three funding rounds. The company's primary mission was to provide essential genomic data on African populations, aiming to enhance drug discovery efforts for global pharmaceutical companies. With less than 3% of genetic material used in global pharmaceutical research sourced from Africa, 54Gene aspired to bridge this significant gap in the global genomics market.


Despite its ambitious goals, 54gene faced internal challenges and underwent significant leadership changes within its four years of existence. Dr. Abasi Ene-Obong, the co-founder and CEO, was replaced, and the company saw three CEO changes in the past year, including Ron Chiarello, who assumed the CEO role in March 2023 but departed in July. These developments mark a period of turbulence and uncertainty for the once-promising genomics startup.

Key Takeaways

Amidst the unfolding developments, there are concerns about the potential repercussions of 54gene's downturn on the genomics and health tech sector. The abrupt decline of a prominent health tech player like 54gene, which had successfully attracted substantial funding, raises apprehensions that global investors may become more hesitant to engage in similar ventures. This uncertainty could cast a shadow over a sector that had previously held great promise for innovation and growth. Adding to the complexity of the situation, Ene-Obong recently launched Syndicate Bio, another genomics company. He had stepped down from his role at 54gene following allegations of financial impropriety made by employees. The interplay of these events underscores the challenges and complexities facing the genomics and health tech sector, with potential ripple effects on investor confidence and the overall trajectory of innovation in the field.

Think someone else should see this?

share on twittershare on linkedinshare on facebookshare to whatsapp
share on mail
share on instagram
Stay informed with our newsletters read by 25,000+ professionals worldwide
Newsletter companiesNewsletter companiesNewsletter companiesNewsletter companiesNewsletter companiesNewsletter companies

Next Frontier

Stay up to date on major news and events in African markets. Delivered weekly.

Pulse54

UDeep-dives into what’s old and new in Africa’s investment landscape. Delivered twice monthly.

Events

Sign up to stay informed about our regular webinars, product launches, and exhibitions.

+25k investors have already subscribed

To invest in this opportunity and other opportunities across Africa

Download the daba finance app on your mobile through
appstore iconappstore icon
Phone Image

Take action.

Download app

Start investing in Africa’s best opportunities, including stocks, bonds, startups, venture funds, and more.

Partner with us

Unlock exciting business opportunities and growth potential.

Join Daba

Become a part of our vibrant community and enjoy exclusive benefits.

Contact us

Reach out to us for inquiries, support, or collaboration.
For Investor
StrategiesPortfolio ManagementAfrican Capital MarketsNews
Daba Pro Intelligence
For Capital Seekers
For StartupsFor Fund ManagersFor Private CompaniesFor Lenders
For Partners
Commercial BanksBroker DealersAsset ManagersInvestment BanksInvestment Advisors and ConsultantsLenders and Microfinance
Company
About UsMarket UpdatesEventsBlog and PodcastNewsletterCase StudiesAffiliate ProgramInvesting GlossaryOfficial ContactsTrust, Compliance and SecurityFrequently Asked Questions

Terms & ConditionsPrivacy Policy
EnglishEnglish

Owned by Daba Markets Inc. By using this site, you accept our Terms and Conditions and Privacy Policy. © 2024 All rights reserved. 2025 All rights reserved